ANTI-TUMOR EFFECT OF TAXOL AND CISPLATIN IN ORAL SQUAMOUS CELL CARCINOMA AND OSTEOSARCOMA CELL LINES.
- Author:
Hoon MYOUNG
1
;
Myung Jin KIM
Author Information
1. Department of Oral and Maxillofacial Surgery School of Dentistry, Seoul National University.
- Publication Type:Original Article
- Keywords:
Taxol;
Chemosensitivity;
Oral squamous cell carcinoma
- MeSH:
Area Under Curve;
Breast Neoplasms;
Carcinoma, Squamous Cell*;
Cell Count;
Cell Line*;
Cells, Cultured;
Cisplatin*;
Enzyme-Linked Immunosorbent Assay;
Humans;
Inhibitory Concentration 50;
KB Cells;
Mouth Neoplasms;
Osteosarcoma*;
Ovarian Neoplasms;
Paclitaxel*
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
1999;25(3):236-241
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECT: Docetaxel(Taxol), which has been used for breast cancer and ovarian cancer and cisplatin were applied to KB and HOS cell lines. Relative cytotoxicity of each drug to cell lines and its efficiency was evaluated and analyzed for clinical application. METHOD AND METERIAL: Groups were defined by drugs and cell lines combination and were evaluated. We cultured cell line under routine environment and determined optimal cell number and drug concentration. Drugs were applied to cell lines and we measured the optical density with ELISA after MTT application. Statistical analysis was made and clinical availability was evaluated. IC50 and assay AUC could be calculated. Clinical availability was evaluated and comparisons of anti-tumor effect of each drug on cell lines were performed. RESULTS: 1. Anti-tumor effects of taxol and cisplatin on each cell lines showed time and dose dependent relations with significance statistically. 2. Assay AUC in IC50 was higher than clinically achievable AUC in all groups except cisplatin-KB group. Anti-tumor effect of taxol to KB cell line was higher than that of cisplatin in concentration calculated from the clinically achievable AUC. So, we could suggest that taxol could be also used as a antitumor durg for oral cancer. Further study that is, in vivo study, evaluation of combination therapy with other drug, and method of increasing of AUC would be necessary.
